SGO 2025: Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer Presented March 18, 2025
SGO 2025: Rinatabart Sesutecan (Rina-S) Shows Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer March 18, 2025
Update relating to Resminostat’s (Kinselby) Marketing Authorisation Application announced March 18, 2025
EU authorises CTA to initiate VIDAR-1 Ph 1/2 umbrella trial in patients with mutated KRAS-positive advanced pancreatic cancer March 18, 2025
U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia March 18, 2025
